Dynamic Technology Lab Private Ltd Takes $1.56 Million Position in Zoetis Inc. (NYSE:ZTS)

Dynamic Technology Lab Private Ltd acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 9,570 shares of the company’s stock, valued at approximately $1,559,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Dunhill Financial LLC increased its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. grew its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares during the period. Murphy & Mullick Capital Management Corp bought a new stake in Zoetis in the fourth quarter worth about $44,000. Finally, Quarry LP lifted its holdings in Zoetis by 45.9% in the 3rd quarter. Quarry LP now owns 305 shares of the company’s stock valued at $60,000 after acquiring an additional 96 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 4.9 %

NYSE:ZTS opened at $151.76 on Friday. The company has a market capitalization of $67.96 billion, a P/E ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. The stock’s 50 day moving average price is $165.71 and its 200 day moving average price is $173.58. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.32%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Piper Sandler lifted their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $215.90.

Insider Activity

In related news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock valued at $312,254. Insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.